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Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is the essential protein for maintenance of the EBV
episome and establishment of latency. The BamHI Q promoter (Qp) is used for the transcription of EBNA-1
mRNA in type I and type II latency, which are EBV infection states exemplified by Burkitt’s lymphoma and
nasopharyngeal carcinoma. However, Qp is inactive in type III latency, and other promoters (the BamHI C
promoter and/or the BamHI W promoter) are used for EBNA-1. The involvement of interferon regulatory
factors (IRFs) in the regulation of Qp is suggested by the presence of an essential interferon-stimulated
response element (ISRE) in the promoter. In this work, expression of IRF-2 is shown to be inversely associated
with Qp status, i.e., IRF-2 levels are high in type III latency (when Qp is inactive) and low in type I latency
(when Qp is active). Also, IRF-2 is identified by electrophoretic mobility shift assay as the major protein
binding to the Qp ISRE in type III latency. In transient transfection assays, IRF-2 represses the activity of
Qp-reporter constructs. Overexpression of IRF-2 in a type I latency cell line did not activate the endogenous
Qp but marginally reduced the EBNA-1 mRNA level. Switching from type III latency (Qp inactive) to type II
latency (Qp active), as produced by cell fusion, is directly associated with greatly reduced expression of IRF-2.
These data strongly suggest that IRF-2 is a negative regulator of Qp and may contribute to the silencing of Qp
in type III latency.

tion of EBNA-1 mRNA. However, in type III latency Qp is
silent, and the BamHI C promoter and/or the BamHI W promoter (C/Wp) are used (see Fig. 1A). The biological consequence of the Qp-to-C/Wp switch and the conversion to type
III latency is the expression of the full spectrum of latency
genes (reviewed in reference 40), which confer enhanced cell
survival, growth, and invasive potential (5, 12, 14, 19, 48, 54,
59).
Since Qp usage not only is essential for the survival of the
virus in an immunocompetent host but also is associated with
several tumors, understanding the regulation of Qp is essential
for understanding the viral program in EBV-associated tumors. Both EBNA-1 and host factors are involved in the transcriptional regulation of Qp. The downstream element of Qp,
the Q locus (see Fig. 3A), contains two binding sites for the
EBNA-1 protein, which binds to them and acts in an autoregulatory manner to repress Qp transcription (43, 50). However,
E2F-1 overcomes EBNA-1-mediated repression of Qp in transient transfection assays, and E2F-1 binds to the Q locus and
displaces the binding of EBNA-1 (49), so that the promoter is
regulated in a cell cycle-dependent manner (8).
An interferon-stimulated response element (ISRE) has been
discovered and appears to be essential for the constitutive
activity of Qp (see Fig. 3A) (32, 44, 61). Interferon regulatory
factors (IRFs), which are a group of transcription factors with
multiple functions (reviewed in reference 30), could potentially
bind to the ISRE and regulate the activity of Qp. A newly
identified IRF-7 has been implicated as a negative regulator of
Qp (61). IRF-2, which is usually a repressor of transcription (3,
9, 11, 15, 17, 18, 20, 27, 28, 35), has been reported to be a major
positive regulator of Qp based on transient transfection assays
in IRF-2-null mouse embryonic fibroblasts (32, 44). The cellular genes activated by IRF-2 that have been identified are the
histone H4 gene (55), as well as vascular cell adhesion molecule-1 (VCAM-1), which is highly cell specific (21).

The biologic hallmark of Epstein-Barr virus (EBV) and its
usual interaction with B lymphocytes is latency. Three types of
latency, each having a distinct pattern of gene expression, have
been described. Type I latency is exemplified by Burkitt’s lymphoma (BL) tumors in vivo and earlier passages of cultured
cell lines derived from BL biopsy specimens. Only EBV nuclear antigen 1 (EBNA-1) is expressed in this form of latency.
Several reports suggest that a type I-like form of latency exists
in healthy carriers of EBV (4, 29, 38, 53). Interestingly, cells in
type I latency can escape host immune surveillance because
EBNA-1 can interfere with its peptide presentation on major
histocompatibility complex class I molecules (25), which might
explain the lifelong reservoir of virus in immunocompetent,
seropositive persons. Type II latency is found in fusions between lymphoblastoid cell lines (LCLs) and epithelial cell
lines, in nasopharyngeal carcinoma and in Hodgkin’s disease.
EBNA-1, latent membrane protein 1 (LMP-1), LMP-2A, and
LMP-2B are expressed in type II latency. Type III latency is
represented by LCLs established after EBV infection of adult
primary B cells in vitro and by group III BL lines. Nine viral
proteins are expressed, including six nuclear proteins (EBNA1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNALP) and three integral membrane proteins (LMP-1, LMP-2A,
and LMP-2B) (reviewed in references 22 and 40).
EBNA-1 is the sole protein needed for the replication of the
EBV episome and maintenance of the latent infection state,
events which are essential for cell immortalization (reviewed in
references 22 and 40). The promoter usage for expression of
EBNA-1 differs in different types of latency. In type I and II
latency, the BamHI Q promoter (Qp) is used for the transcrip* Corresponding author. Mailing address: Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7295,
Chapel Hill, NC 27599. Phone: (919) 966-3036. Fax: (919) 966-9673.
E-mail: luzhang@med.unc.edu.
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Perhaps the most intriguing aspect of Qp is how it is rendered inactive selectively in type III latency. Since any IRF
could potentially bind to the Qp ISRE, the possibility that
IRFs other than IRF-7 are involved in the inactivation of Qp
was raised. The data presented in this paper suggest that IRF-2
acts as a constitutive repressor of Qp in type III latency.
MATERIALS AND METHODS
Cell culture. DG75 is an EBV-negative BL line (2). Sav I and Sav III, and Kem
I and Kem III, are paired EBV-positive BL lines that differ only in their latent
infection types (33, 41). CB95, X50-7, SFC-4, and KR-4 are LCLs (23, 34, 57).
Jijoye is an EBV-positive type III BL line, and Akata is a type I BL line (51).
FaDuHyg is a head-and-neck squamous carcinoma line (39). All these lines were
maintained in RPMI-1640 plus 10% fetal bovine serum (FBS). KH-1 and KH-2
lines were derived from fusion of KR-4 (LCL) and HeLa (cervical carcinoma)
cells (6). DKO is a mouse embryonic fibroblast line with targeted disruption of
both the IRF-1 and the IRF-2 gene (28). KH-1, KH-2, HeLa, and DKO were
maintained in Dulbecco’s modified Eagle medium (DMEM) plus 10% FBS.
Plasmids and antibodies. IRF-2 and IRF-7A expression plasmids and IRF-7
antibody have been described elsewhere (35, 61). pcDNA/CD4 is a human CD4
expression plasmid (a gift from J. Ting). The b-galactosidase expression plasmid,
pCMVb (6177-1), was purchased from Clontech, pQ1-CAT (2173 to 1116 relative to the Qp start site) was obtained by removal of a HindIII-BamHI fragment
from pF2-CAT (49), while pQ2-CAT (2173 to 15) was made by cloning the
corresponding PCR fragment into pBS-CAT (10). The anti-IRF-1 (C-20) and
anti-IRF-2 (C-19) antibodies were purchased from Santa Cruz Biotechnology,
Inc. The anti-g-tubulin antibody (T-6557) was from Sigma. The Western blot
analysis with enhanced chemiluminescence (ECL) and protein assay were carried out essentially as described elsewhere (42, 61).
Transient transfection and isolation of transfected cells. For DG75, Akata,
and Jijoye cells, 107 cells in 0.5 ml of medium were used for transfection with a
Bio-Rad Gene Pulser (at 320 V and 975 mF). For FaDuHyg cells, Superfect
transfection reagents were used according to the manufacturer’s recommendations (Qiagen). For DKO cells in 60-mm culture dishes with 40 to 60% confluence, 24 mg of Lipofectamine reagents (GIBCO BRL) in 400 ml of serum-free
Opti-MEM (GIBCO BRL) was mixed gently with another 400 ml of Opti-MEM
containing 7.5 mg of DNA. These mixtures were then gently shaken at room
temperature for 15 min, and 1 ml of serum-free medium was added before
application to DKO cells, which were rinsed once with serum-free medium. After
2 h of incubation in a 37°C incubator, the cells were rinsed again with complete
DMEM. Two days after transfection, cells were collected for chloramphenicol
acetyltransferase (CAT) assay or for isolation of transfected cells. The CAT and
b-galactosidase assays were essentially the same as described elsewhere (24, 42,
61). The CAT assay results were analyzed on a Molecular Dynamics PhosphorImager.
For isolation of transfected cells, cells were collected and CD4-positive cells
were enriched by use of anti-CD4-antibody-conjugated magnetic beads according to the manufacturer’s recommendation (Dynal, Inc.). These cells were used
for the isolation of total RNA with the RNase kit (Qiagen).
RPA. RNase protection assays (RPAs) were performed with total RNA by use
of the U.S. Biochemicals RPA kit. The hybridization temperature was 37°C. The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was provided by
U.S. Biochemicals, Inc. The EBNA-1 probe was generated by PCR with the
Extend high-fidelity PCR system (Boehringer Mannheim) and specific primers.
The sequence of primer A is 59-GCTCTAGATAATACGACTCACTATAGGG
CGACAGACCCAAGCTTGGTACCGAGCTCGGATCCTGTCATAACAAG
GTCCTTAATCGCA-39, and that of primer B is 59-GCTCTAGAGACTACCG
ACGAAGGAACTTGG-39. Primer A contains the T7 RNA polymerase promoter sequence to allow the transcription of the antisense EBNA-1 RNA probe
and a spacer to provide separation between the unprotected and protected regions of the probe in the RPA. The protected region of EBNA-1 corresponds to
nucleotides (nt) 109437 to 109704 of the EBV B95-8 strain. The purified PCR
product was confirmed by enzymatic digestion and used directly for RNA probe
synthesis by use of T7 RNA polymerase (Promega) and [a-32P]UTP (Amersham). The H4 histone probe was also generated by PCR with specific primers
in a manner similar to that for EBNA-1. The sequences of primers used are
59-GCTCTAGATTAAGCGGATCTCTGGCCTCAT-39 and 59-GCTCTAGAT
AATACGACTCACTATAGGGCGACAGACCCAAGCCTTGGTACCGAGC
TCGGATCCCTAGCCTCCGAAGCCGTAGAGGGTTCTC-39. The protected
region corresponds to nt 743 to 924 of the published sequence (36).
EMSA. Cell lysates were made and an electrophoretic mobility shift assay
(EMSA) was performed essentially as described elsewhere (26, 37, 61). When
antiserum was needed, 1 ml was added to the reaction mixture. The Qp ISRE
probe is the same as F7/8, which has a 21-bp region from Qp (61).
RT-PCR for detection of Qp and C/Wp. C/Wp and Qp activities were detected
by reverse transcription-PCR (RT-PCR) with primer pairs which can distinguish
the use of C/Wp from that of Qp (53). After RT-PCR, the products were
separated on a 2% agarose gel, transferred to a nitrocellulose membrane, and
probed with labeled primers for specific detection of either the C/Wp- or the Qpderived PCR product. C/Wp activity was determined by the detection of both

FIG. 1. Correlation of Qp status and IRF-2 expression. (A) Schematic diagram of Qp status in EBV latency states. The arrows indicate that conversions
can happen naturally or be forced in cell culture. (B) IRF-2 is associated with
type III latency. Equal amounts of protein lysates were electrophoresed in
sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis and stained with
Ponceau S Red after the transfer of protein to the membrane. Western blotting
with IRF-1 or IRF-2 antibodies was performed. Lanes 1 to 6, cell lysates from
Sav I (type I), Sav III (type III), Kem I (type I), Kem III (type III), Akata (type
I), and CB95 (type III), respectively.

EBNA-2 and EBNA-1 (Y3/U/K spliced form) mRNAs. Qp activity was determined by detection of the Q/U/K spliced form of EBNA-1 mRNA. F promoter
(Fp) activity was determined by detection of the F/U/K form of EBNA-1 mRNA
(45) by use of induced Akata cDNA as a positive control. The F19 oligonucleotide (59-gctctagaGAGAGGAGGGGGATCCGGAG-39, corresponding to nt 62239
to 62258) was used as a primer for the BamHI F region. (The lowercase letters
stand for the non-EBV sequences.) All the other primers and probes were the
same as reported elsewhere (53). With reference to the B95-8 genomic sequence,
the genome coordinates for these primers and probes are 62440 to 62457, 107986
to 107967, 14802 to 14822, 48583 to 48562, 67544 to 67563, 48397 to 48416, and
47855 to 47904 (53).

RESULTS
Expression of IRF-2 is associated with EBV type III latency.
The association of IRF-7 with EBV type III latency has been
established (61), and the levels of expression of other IRFs
were investigated. Specifically, the expression of IRF-1 and
IRF-2 was examined by Western blot analysis with specific
antisera against IRF-1 or IRF-2 proteins. Sav I and Sav III, as
well as Kem I and Kem III, are paired, genetically identical
EBV-infected cell lines that differ only in their types of latency
(33, 41). As shown in Fig. 1B, IRF-2 is expressed at much
higher levels in type III latency (Fig. 1B, lanes 2 and 4) than in
type I latency (lanes 1 and 3). IRF-2 is also expressed at higher
levels in SFC-4, CB95, X50-7, and Jijoye cells (all type III) than
in Akata cells (type I) (Fig. 1B, lanes 5 and 6; Fig. 3D, lanes 1
and 2; also data not shown) (34, 51). In contrast, the IRF-1
level is basically unchanged in type I and III cells. The types of
latency were confirmed by detection of LMP-1, EBNA-1, and
EBNA-2 proteins. In all the cell lines tested, the expression of
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FIG. 2. IRF-2 is the major protein binding to the Qp ISRE in type III cells.
(A) Patterns of binding to the Qp ISRE in type I and type III cells. The probe
was Qp ISRE labeled with [a-32P]dCTP. Free probe (lane 1) and lysates from
Akata (lane 2), CB95 (lanes 3 to 8), Sav I (lane 9), and Sav III (lane 10) cells were
used for EMSA. Cold competitor (the Qp ISRE) was added in lane 4 at a
100-fold molar excess over the hot probe. The following antibodies were added:
preimmunization serum (lane 5), IRF-7 antiserum (lane 6), a-IRF-1 antiserum
(lane 7), and a-IRF-2 antiserum (lane 8). Arrows with question mark indicate a
band found primarily in type I cell lysates. (B) Sequence comparison between a
sequence selected randomly by IRF-2 binding and the Qp ISRE.

IRF-2 is higher in type III cells than in type I cells. These data
show that a high level of expression of IRF-2 is associated with
type III latency and suggest that IRF-2 is a negative regulator
of Qp because Qp is inactive in type III latency.
IRF-2 is the major protein binding to the Qp ISRE in type
III latency. Since the Qp ISRE is essential for Qp activity (50,
61), the binding of various IRFs to Qp is likely to be informative about their relative contributions to the regulation of Qp.
An EMSA was used to examine the protein-binding pattern
generated with this element in type I and type III cell extracts.
Lysates were prepared from Akata (type I) and CB95 (type III)
cells, and equal amounts of protein were used with the Qp
ISRE as the probe. There are clear differences in the proteinbinding patterns with type I and III cell lysates (Fig. 2A). In
CB95 lysates, a major band was detected that disappeared
when the cold Qp ISRE competitor (1003) was used (Fig. 2A,
lane 4) but not by competition with mutated or unrelated
probes (data not shown). The protein in that band was identified as IRF-2 by supershifting produced with an IRF-2 antibody and not with IRF-7 or IRF-1 antibodies (Fig. 2A, lanes 5
to 8). Almost identical results could be obtained when SFC-4
(type III) lysate was used for supershift analysis. Under several
EMSA conditions tested, IRF-2 was always the major binding
protein. As expected, IRF-2 binding was barely detectable with
the type I extracts (Fig. 2A, lanes 2 and 9); a large amount of
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protein from Akata cells was required to detect any binding
(data not shown). Similar results were obtained with the paired
cell lines, such as Sav I and Sav III (Fig. 2A, lanes 9 and 10).
The clear difference in binding of IRF-2 produced with extracts
from type I and III cells was consistent with the levels of IRF2 detected in Western blot analysis (Fig. 1B).
That IRF-2 is the major protein binding to the Qp ISRE in
EMSA suggests that IRF-2 has a high affinity for the Qp ISRE.
This point is supported by a previous report that a sequence
identical to the core sequence of the Qp ISRE could be selected randomly from an oligonucleotide pool by IRF-2 binding (Fig. 2B) (52).
Interestingly, binding of IRF-1 and IRF-7 to Qp was hardly
detectable in this assay (Fig. 2A, lanes 6 and 7). Although IRF7 is consistently associated with type III latency in all the cell
lines tested by Western blot analysis, and in vitro-made IRF-7
binds to Qp, binding of IRF-7 was not detected with cell lysates
despite extensive efforts (61). Because IRF-7 itself was cloned
based on its binding to the Qp ISRE in a yeast one-hybrid
system, it is conceivable that IRF-7 can bind to Qp with low
affinity in vivo. Similarly, binding of IRF-1 is hard to detect
with cell lysates, although it can bind to Qp in vitro (data not
shown). It seems likely that in the presence of IRF-2, other
IRFs compete with difficulty for binding to the Qp ISRE. In
support of this notion, the IRF-1-Qp ISRE complex could be
identified in lysates of an IRF-2-null line (44), which again
suggests that IRF-2 has a higher affinity for Qp.
Overexpression of IRF-2 represses activity of Qp-reporter
constructs. The effect of IRF-2 on the activity of Qp was examined by use of Qp-reporter constructs in transient transfection assays. Since EBV can infect epithelial cells, the FaDuHyg
epithelial line (39), which has low endogenous expression of
both IRF-2 and IRF-7, was chosen for reporter assays. Cotransfection of an IRF-2 expression plasmid with pQ2-CAT, a Qp
reporter construct containing the ISRE sequence (Fig. 3A), resulted in a decrease in the constitutive activity of Qp (;80%
[Fig. 3B]). As expected, IRF-7 also repressed pQ2-CAT activity (Fig. 3B). Repression was also observed when pQ1-CAT
(Fig. 3A) was used for this experiment (Fig. 3B). IRF-1 has
little or no effect on these reporter constructs. No repression
by IRF-2 was observed when pFe3M (50), which has point
mutations in the ISRE that abolish binding of IRF-2, was used
as a reporter. Also, no repression was observed when pBSCAT was used as a reporter, and IRF-2 could weakly activate
a histone H4 reporter construct in this cell line (55) (data not
shown). The data here indicate that IRF-2, as well as IRF-7,
represses Qp activity.
Repression by IRF-2 of pQ2-CAT, which lacks the Q locus
(Fig. 3A), could be detected consistently, although at low levels, in B-cell lines (e.g., DG75 cells); however, repression of the
pQ1-CAT reporter construct, which contains the Q locus, was
hard to detect in B-cell lines as reported elsewhere (32) (data
not shown). These data suggest that the Q locus may contain a
positive regulatory element(s) which overcomes the repression
of IRF-2. A likely candidate might be an E2F family member(s) (49). In support of this notion, the constitutive activity of
pQ1-CAT is about fourfold higher than that of pQ2-CAT (Fig.
3B).
To address whether physiological levels of IRF-2 and IRF-7
might inhibit Qp, Akata (type I) and Jijoye (type III) cell lines
were transfected with Qp-reporter constructs along with a bgalactosidase expression plasmid. Akata and Jijoye lines were
chosen because they have similar transfection efficiencies, and
expression levels of both IRF-2 and IRF-7 are higher in Jijoye
than in Akata cells, as expected (Fig. 3D and data not shown).
As shown in Fig. 3C, the constitutive activities of Qp-reporter
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FIG. 3. Repression of Qp-reporter constructs by IRF-2. (A) Schematic diagram of Qp and Qp-reporter constructs. Open rectangle, ISRE; solid bars, E2F binding
sites; ovals, EBNA-1 binding sites (Q locus). The RNA start site for Qp is indicated by an arrow (46). (B) Repression of Qp by IRF-2. The pQ1-CAT and pQ2-CAT
reporter constructs were cotransfected with pCMVb and either pcDNA3 plasmids, pCMV-IRF-2, or pcDNA-IRF-7A. Transfection efficiency was normalized by
b-galactosidase activity. The relative CAT activities from three experiments are shown with standard deviations. (C) Constitutive activities of Qp reporters in type I
and type III cell lines. Akata (type I) and Jijoye (type III) cell lines were used for transfection with Qp reporters and pCMVb. Transfection efficiency was normalized
by b-galactosidase activity. The relative CAT activities from four replicates are shown with standard deviations. (D) Endogenous levels of IRF-2 in type I and type III
cell lines. Equal amounts of protein lysates were electrophoresed in sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis and stained with Ponceau S Red
after the transfer of protein to the membrane. Western blotting with IRF-1 or IRF-2 antibodies was performed. Cell lysates from the Akata (type I) and Jijoye (type
III) cell lines were used.

constructs are lower in the Jijoye cell line than in Akata cells.
The greater difference in the activity levels of pQ1-CAT between type I and type III latency cells is most likely due to the
effect of the additional repressor, EBNA-1 (Fig. 3A) (43, 50).
Although other factors may also contribute to the lower activity of Qp in type III cells, the results suggest that physiological
levels of IRF-2 and IRF-7 can repress Qp.
IRF-2 did not activate endogenous Qp. Next, the role of
IRF-2 in the regulation of endogenous Qp was addressed by
overexpression of IRF-2 in a type I line in an attempt to mimic
the high expression of IRF-2 in type III cells. Several attempts
to generate a cell line stably expressing IRF-2 failed, and a
system that can enrich for transfected cells was used instead.
By cotransfection of a CD4 expression plasmid, transfected
cells were selected with the use of CD4 antibody-conjugated
magnetic beads (see Materials and Methods for details). Akata
cells were chosen because of their relatively higher transfection
efficiency. Total RNA from vector and IRF-2-transfected cells
was extracted, and RPAs were performed with an EBNA-1specific probe. As shown in Fig. 4, IRF-2 did not activate Qp
but marginally reduced the Qp-derived EBNA-1 mRNA (compare lanes 4 and 5). DG75 cells, an EBV-negative BL line, did
not show an EBNA-1 RNA band (lane 2 and 3). Only low
levels of EBNA-1 mRNA could be detected in type I cells (Fig.
4) (33), which is consistent with the low abundance of Qpderived EBNA-1 mRNA in type I cells (8).
Since IRF-2 has been reported to be a positive regulator of
the H4 histone promoter (55), the H4 histone mRNA level was

examined. IRF-2 could activate the histone H4 gene only slightly, as reported elsewhere (55), and no repression could be
observed as determined by RPA with an H4-specific probe.
IRF-2 apparently has minimal effect on histone H4 in B-cell
lines because no obvious differences in H4 histone mRNA
levels were observed in a panel of type I and III lines (data not
shown).
The amount of reduction of the EBNA-1 mRNA (;50%)
observed in an RPA was consistent with the degree of repression obtained in the Qp reporter assays (Fig. 3B, bars 1 and 2).
These results suggest that IRF-2 is likely to be a repressor, and
not an activator, of Qp. The partial reduction of EBNA-1
mRNA detected might be due to the need for more than one
repressor to silence Qp (see Discussion), to low enrichment
efficiency of transfected cells, or to cotransfection efficiency.
Also, IRF-2 may have to compete with a Qp activator(s), which
is likely to be specific for type I cells. An additional complex
binding to Qp ISRE was consistently detected in type I cell
lysates (Fig. 2A, lanes 2 and 9) and might be a candidate for a
Qp activator. This complex apparently does not contain IRF-1,
because IRF-1 antibody could not supershift and/or block this
complex (data not shown).
Qp reactivation is associated with down-regulation of IRF2 and IRF-7. It has been clearly shown that fusion of a type III
cell line with an epithelial cell line can force a switch from the
type III to the type II latency phenotype (6). KR-4 (a type III
LCL) and HeLa (EBV-negative cervical carcinoma cells) are
parental lines for the KH-1 and KH-2 lines produced by cell

3220

ZHANG AND PAGANO

MOL. CELL. BIOL.

where Qp is inactive, to type II latency, where Qp is reactivated, is associated with striking reductions in the levels of
IRF-2 and IRF-7, supporting the roles of IRF-2 and IRF-7 as
negative regulators of Qp.
DISCUSSION
The switch from Qp to C/Wp, which allows transcription of
all the other EBNA proteins (EBNA-2, -3A to -3C, and -LP),
produces a phenotypic conversion to type III latency. We previously identified an ISRE in Qp and a novel protein, IRF-7, as
a putative negative regulator for this promoter (61). In this
work, IRF-2 was also found to be strongly associated with type
III latency and to act as a negative regulator of Qp.
It is becoming clear that IRFs are involved in the regulation

FIG. 4. IRF-2 did not activate endogenous Qp. (Top) EBNA-1 and GAPDH
probes were labeled with [a-32P]UTP and used for RPA. RNAs from Akata cells
(lane 1), DG75 cells (lanes 2 and 3), or Akata cells transfected with pcDNA3
(lane 4) or pCMV-IRF-2 (lane 5) were used. The reduction of EBNA-1 mRNA
by IRF-2 was 45%, which was obtained by normalizing EBNA-1 levels to
GAPDH by use of a PhosphorImager. Specific protection of EBNA-1, GAPDH
mRNA, and undigested probe is indicated. (Bottom) Short exposure time for
protected GAPDH mRNA. The sizes, which were confirmed by molecular weight
markers, are shown on the left in nucleotides.

fusion (Fig. 5A) (6). That KH-2 and KH-1 are type II latency
cells was confirmed by the detection of EBNA-1 and LMP-1
but not EBNA-2 proteins (data not shown). The absence of
C/Wp activity in KH-1 and KH-2 lines has previously been
reported, but without addressing the Qp status (1). Here we
show that Qp is reactivated and C/Wp is inactivated in both
fusion cell lines, as expected in cells with a type II phenotype
(40), in contrast to the parental KR-4 line, in which C/Wp is
active and Qp is inactive (Fig. 5C). The lytic promoter, BamHI
F (Fp [45]), is not active in these lines (see Materials and
Methods for details). Finally, the percentage of cells containing EBV genomes was examined by using EBER staining followed by fluorescence-activated cell sorter analysis (7). The
KH-2 and KR-4 lines have identical amounts of EBER-positive cells, while KH-1 has a relatively lower percentage (data
not shown).
Since Qp was reactivated in the KH-1 and KH-2 lines, the
expression of IRF-2 and IRF-7 was examined by Western blot
analysis. As shown in Fig. 5B, IRF-2 is expressed at much
higher levels in the parental KR-4 cells than in the KH-1 and
KH-2 lines. As expected, IRF-7 is also greatly reduced (61).
These data indicate that switching from type III latency,

FIG. 5. Reactivation of Qp is associated with down-regulation of IRF-2 and
IRF-7 expression. (A) Schematic diagram for generation of KH cell lines (6). (B)
Expression of IRF-2 and IRF-7 is down-regulated in type II latency. Cell lysates
from KR-4, KH-1, KH-2, and HeLa cells were used for Western blot analysis.
g-Tubulin was used as a loading control. (C) Qp and C/Wp activities in the cell
lines. The promoter activities were determined by RT-PCR with Qp- or C/Wpspecific primers followed by Southern blot analysis. Double-distilled water
(ddH2O) or cDNAs from the cell lines shown were used.
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FIG. 6. Activation of Qp-reporter constructs by IRF-2 in a mouse IRF-2-null
cell line. DKO, a mouse embryonic fibroblast line in which both IRF-1 and IRF2 genes are disrupted (28), was used for transfection. The pQ1-CAT and pQ2CAT reporter constructs were cotransfected with pcDNA3 plasmids or pCMVIRF-2. The amounts of plasmids transfected are shown at the top. pCMVb was
also cotransfected, and b-galactosidase activity was used to normalize transfection efficiency. The relative CAT activities and standard deviations are shown.

of Qp. Although IRF-2 is reported to be a transactivator that
can activate the histone H4 gene and VCAM-1 (21, 55), IRF2 is usually a transcriptional repressor and an antagonist to
IRF-1 (3, 9, 11, 15, 17, 18, 20, 27, 28, 35). It is interesting that
IRF-2 has been reported to be the major positive regulator of
Qp in mouse fibroblasts (32, 44). However, the data presented
here suggest strongly that IRF-2 is a negative regulator of Qp.
First, IRF-2 expression is associated with EBV type III latency,
where Qp is inactive (Fig. 1, 2, and 3D); second, overexpression of IRF-2 in a type I line did not activate Qp but marginally
reduced the level of EBNA-1 mRNA derived from Qp (Fig. 4);
third, IRF-2 is the major protein binding to Qp and appears to
have a high affinity for its ISRE (Fig. 2); fourth, IRF-2 represses the activity of Qp-reporter constructs in transient
transfection assays (Fig. 3); and fifth, Qp reactivation in type II
cells converted by cell fusion from type III cells, in which Qp is
inactive, is associated with a sharp reduction in the expression
of IRF-2 (Fig. 5).
Previous reports that IRF-2 activates Qp may be due to the
mouse fibroblast lines that were used (32, 44). Indeed, IRF-2
could activate our Qp-reporter constructs in a mouse IRF2-null fibroblast line from the same source (Fig. 6). However,
these results must be interpreted in relation to their biological
relevance. Selection of an appropriate line is especially important for IRF-2 research because IRF-2 possesses both a transcriptional repression domain and a latent activation domain
(58). If the repressor domain of IRF-2 is not active in a given
cell line, the latent activation domain may be activated, and
IRF-2 becomes an activator. This scenario is documented in
muscle cells, where IRF-2 can activate the VCAM-1 promoter
(21). Since EBV infects neither fibroblasts nor rodent cells, the
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conclusion based solely on reporter assays conducted in mouse
fibroblasts raises questions about biological relevance. In contrast, our results were obtained with human cell lines latently
infected or infectible with EBV.
Another explanation for the different results is that IRF-2
might have a dual function in the regulation of Qp, i.e., it might
positively regulate Qp in type I cells when the IRF-2 level is
low and negatively regulate Qp in type III cells when expression of IRF-2 is high. Data from transfections of Qp into an
IRF-2-null line with high doses of IRF-2 may suggest such a
tendency (Fig. 6). This possibility needs to be rigorously addressed. However, a dose-dependent repression of Qp by IRF2 could be observed in biologically relevant lines, such as
FaDuHyg and DG75 (data not shown).
Other than being a regulator of Qp, IRF-2 may also contribute to the transforming properties of EBV in type III latency. EBV can immortalize primary B cells and, at the same
time, establish type III latency. IRF-2 has oncogenic potential
based on transformation assays (16, 31). It would be interesting
to examine EBV-associated immunoblastic lymphomas (type
III latency) directly to see if IRF-2 levels are elevated in these
malignancies.
The inducer(s) of IRF-2 in type III cells is still unclear, although LMP-1 can stimulate the expression of IRF-7 (62). Further work needs to be done to identify the inducer(s) of IRF-2 in
type III latency. Other possibilities are that the type I latency
cells, in which IRF-2 and IRF-7 levels are low, are selected by
EBV for infection; or that establishment of type I latency itself
involves the down-regulation of IRF-2 and IRF-7.
IRF-7 was cloned as a Qp-binding protein and subsequently
inferred to be a negative regulator of Qp (61). This function is
further supported by the fact that reactivation of Qp by fusion
of type III cells with epithelial cells to produce cells with a type
II phenotype is associated with a striking reduction in the expression of IRF-7 (Fig. 5). Other than being a Qp repressor, an
additional role of IRF-7, namely, virus-induced activation of
the interferon-b gene, has just been reported (56).
It is interesting that both IRF-2 and IRF-7 are negative
regulators of Qp. There was no apparent synergistic effect between these two factors in terms of Qp repression, and an additive effect was hard to detect when both were overexpressed
(data not shown). Why would Qp use two repressors for a single ISRE site? One possible explanation is that IRF-2 and
IRF-7 are apparently expressed at different times during the
cell cycle (60). Therefore, IRF-2 and IRF-7 may functionally
repress Qp in different phases of the cell cycle to keep Qp
silenced throughout the cycle.
Apart from IRF-2 and IRF-7, viral proteins definitely play
an important role in the silencing of Qp. EBNA-1 can directly
repress Qp activity (43, 50), and the higher levels of the protein
in type III latency may enhance its repressor effect (references
8, 13, and 47 and our unpublished results). EBNA-2, which is
responsible for the increased expression of EBNA-1 in type III
latency, could be considered an indirect regulator of Qp.
It is clear that Qp regulation is complicated and that multiple factors, both viral and cellular, are involved. With IRF-2,
IRF-7, and EBNA-1 all expressed at higher levels in type III
latency, it is reasonable to infer that Qp may be turned off by
a combination of IRF-2, IRF-7, EBNA-1, and perhaps another
repressor(s), i.e., IRF-2 and IRF-7 may repress Qp through its
ISRE while EBNA-1 acts through the Q locus (Fig. 3A). In
contrast, in type I latency, when Qp is active, all these factors
are expressed at much lower levels. The major positive regulator(s) of Qp operating through the ISRE is unidentified but
apparently is associated with type I latency. A band which
seems to be specific for type I cells was detected by EMSA
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(Fig. 2) and was also noticed by other investigators (32); it
might be a candidate for such an activator.
Thus, we show that IRF-2, probably acting with IRF-7, and
perhaps EBNA-1 as well, silences the promoter used in the
most-restricted form of EBV latency, type I, with the indirect
consequence that the promoter for the least-restricted form of
EBV latency, type III, is used. It is likely that several IRFs,
both positive and negative regulators, that have different affinities for the type I promoter and are supplied at different
times in the cell cycle, govern the activity of this key, tightly
regulated EBV promoter.
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